Recombinant Human Bone Morphogenetic Protein-3B 屬于轉(zhuǎn)化生長因子 β 超家族，與骨形態(tài)發(fā)生蛋白-3 (BMP3) 密切相關(guān)。Recombinant Human Bone Morphogenetic Protein-3B 在頭部形成中起作用，且在骨骼形態(tài)發(fā)生中具有多種作用。
Synonyms
rHuBMP-3B; BIP; BMP-3B; GDF-10
Species
HumanSource
E. coli Accession
P55107 Gene ID
2662 Molecular Weight
Approximately 25.1 kDa AA Sequence
MQWDEPRVCS RRYLKVDFAD IGWNEWIISP KSFDAYYCAG ACEFPMPKIV RPSNHATIQS IVRAVGIIPG IPEPCCVPDK MNSLGVLFLD ENRNVVLKVY PNMSVDTCAC R Appearance
Lyophilized powder. Formulation
Lyophilized after extensive dialysis against 4 mM HCl. Endotoxin Level
<0.2 EU/μg, determined by LAL method. Reconstitution
Reconstitute the lyophilized recombinant Human Bone Morphogenetic Protein-3B (rHuBMP-3B) to 100 μg/mL using 4 mM HCl. Storage & Stability
Lyophilized recombinant Human Bone Morphogenetic Protein-3B (rHuBMP-3B) is stored at -20°C. After reconstitution, it is stable at 4°C for 2 weeks or -20°C for longer. It is recommended to freeze aliquots at -20°C or -80°C for extended storage. Shipping
Room temperature in continental US; may vary elsewhere. Background
The transforming growth factor-beta (TGF-beta) superfamily includes more than 30 members which have a broad array of biological activities. TGF-beta superfamily ligands bind to type II and type I serine/threonine kinase receptors and transduce signals via Smad proteins. Receptor-regulated Smads (R-Smads) can be classified into two subclasses, i.e. those activated by activin and TGF-beta signaling pathways (AR-Smads), and those activated by bone morphogenetic protein (BMP) pathways (BR-Smads). The numbers of type II and type I receptors and Smad proteins are limited. Thus, signaling of the TGF-beta superfamily converges at the receptor and Smad levels. In the intracellular signaling pathways, Smads interact with various partner proteins and thereby exhibit a wide variety of biological activities. Moreover, signaling by Smads is modulated by various other signaling pathways allowing TGF-beta superfamily ligands to elicit diverse effects on target cells. Perturbations of the TGF-beta/BMP signaling pathways result in various clinical disorders including cancers, vascular diseases, and bone disorders[1]. |
